Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 11, Issue SUPPL.3, 2009, Pages 4-10

  Sesti, G ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Glucagon like peptide 1; Incretin; Obesity; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; INCRETIN;

ANIMAL; ARTICLE; BODY WEIGHT; DRUG EFFECT; HUMAN; INSULIN RESISTANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN RESISTANCE; OBESITY; WEIGHT LOSS;

EID: 73349113538     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01072.x     Document Type: Article

References (47)

1. International Diabetes Federation. Diabetes Atlas, 2nd edn. Brussels: IDF, 2003.
2. Nelson KM, Reiber G, Boyko EJ. Diet and exercise among adults with type 2 diabetes. Diabetes Care 2002; 25: 1722-1728.
3. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961-969.
4. Frühbeck G. Overview of adipose tissue and its role in obesity and metabolic disorders. In: Yang K ed. Adipose Tissue Protocols. Methods in Molecular Biology. Totowa: Humana Press, 2008; 1-22.
5. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372.
6. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
7. Russell Jones D, Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies. Diabetes Obes Metab 2007; 9: 799-812.
8. Purnell JQ, Hokanson JE, Marcovina SM et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA 1998; 280: 140-146.
9. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes 2002; 26 (Suppl. 3): S18-S24.
10. Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008; 34: S65-S72.
11. Zander M, Madsbad S, Lysgaard M et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
12. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913.
13. Flint A, Raben A, Astrup A et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
14. Wettergren A, Schjoldager B, Mortensen PE et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673.
15. Düring MJ, Cao L, Zuzga DS et al. Glucagon-like peptide 1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173-1179.
16. Turton MD, O'Shea D, Gunn I et al. A role for glucagons-like peptide 1 in the central regulation of feeding. Nature 1996; 379: 69-72.
17. Näslund E, Bogefors J, Skogar S et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol Regul Integr Comp Physiol 1999; 277: 910-916.
18. Gutzwiller JP, Drewe J, Göke B et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol Regul Integr Comp Physiol 1999; 276: R1541-R1544.
19. Verdich C, Flint A, Gutzwiller AP et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382-4389.
20. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
21. Knudsen LB, Nielsen PF, Huusfeldt PO et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once-daily administration. J Med Chem 2000; 43: 1664-1669.
22. Raun K, Von Voss P, Knudsen LB. Liraglutide, a once-daily human glucagons-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity 2007; 15: 1710-1716.
23. Szayna M, Doyle ME, Betkey JA et al. Exendin-4 decelerates food intake, weight gain and fat deposition in Zucker rats. Endocrinology 2000; 141: 1936-1941.
24. Garber A, Henry R, Garcia-Hernandez PA et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
25. Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
26. Nauck MA, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009; 32: 84-90.
27. Zinman B, Gerich J, Buse J et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met + TZD). Diabetes Care 2009; 32: 1224-1230.
28. Russell-Jones D, Vaag A, Schmitz O et al, on behalf of the LEAD-5 (Liraglutide Effect and Action in Diabetes 5) met + SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met + SU). Diabetologia 2009; 52: 4026-4055.
29. Russell-Jones D, Shaw JE, Brandle M et al. The once-daily human GLP-1 analog liraglutide reduces body weight in subjects with type 2 diabetes, irrespective of body mass index at baseline (Abstract 2147-PO). Diabetes 2008; 57 (Suppl. 1): A593.
30. Redon J, Cifkova R, Laurent S. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008; 26: 1891-1900.
31. Barzilai N, Gabriely I. The role of fat depletion in the biological benefits of caloric restriction. J Nutr 2001; 131: 903S-906S.
32. Jendle J, Nauck MA, Matthews D. Liraglutide, a once-daily human GLP-1 analog, reduces fat percentage, visceral and subcutaneous adipose tissue and hepatic steatosis compared with glimepiride when added to metformin in subjects with type 2 diabetes (Abstract 106-OR). Diabetes 2008; 57 (Suppl. 1): A32.
33. Snijder MB, Van Dam RM, Visser M et al. What aspects of body fat are particularly hazardous and how do we measure them? Int J Epidemiol 2006; 35: 83-92.
34. Lebovitz HE, Banerji MA. Point: visceral adiposity is causally related to insulin resistance. Diabetes Care 2005; 28: 2326-2328.
35. Brodows R, Milton D, Ridge TD et al. Exenatide monotherapy improves glycemic control and is well tolerated over 24 weeks in drug-naïve patients with type 2 diabetes (Abstract 485-P). Diabetes 2008; 57 (Suppl. 1): A145.
36. DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
37. Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
38. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
39. Mack CM, Moore CX, Jodka CM et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006; 30: 1332-1340.
40. Zinman B, Hoogwerf BJ, Durán García S et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007; 146: 477-488.
41. Buse JB, Rosenstock J, Sesti G et al. A study of two glucagon-like peptide-1 receptor agonists for the treament of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomised, 26-week, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
42. Flint A, Kapitza C, Hindsberger C et al. The once-daily human GLP-1 analogue liraglutide decreases postprandial hunger and energy intake. Diabetes 2008; 57 (Suppl. 1): A165 (555-P).
43. Edwards CMA, Stanley S, Davis R et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155-E161.
44. DeFronzo A, Okerson T, Viswanathan P et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24: 2943-2952.
45. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
46. Aschner P, Kipner MS, Lunceford JK et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637.
47. Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 2006; 57: 265-281.